Arvinas, Inc. (NASDAQ:ARVN) is one of the best US stocks under $10 to invest in, with XTX Topco Ltd increasing its stake by 194.2% in the first quarter, holding 78,257 shares valued at $549,000.

Arvinas, Inc. (NASDAQ:ARVN) reached a milestone with Pfizer to co-develop Vepdegestrant, targeting advanced breast cancer. The U.S. FDA is set to review the drug’s marketing application with a target action date of June 5, 2026, to address unmet medical needs.

Arvinas, Inc. (NASDAQ:ARVN) is a Connecticut-based biotech company focused on PROTAC technology to degrade disease-causing proteins, with significant clinical and regulatory programs. Management is confident in advancing its programs with a robust balance sheet.

While ARVN is a promising investment, other AI stocks may offer greater upside potential. For undervalued AI stocks benefitting from Trump-era tariffs and onshoring trend, consider our free report on the best short-term AI stock.

Disclosure: None.

Read more at Yahoo Finance: Arvinas, Inc. (NASDAQ:ARVN) Stake Jumps 194% at XTX Topco